ArticleDiscover oncology2025
Identification of benign from malignant small renal tumors: is there a possible role of T1 mapping?
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Utility of Quantitative MRI Parameters for Differentiation of Renal Tumor Subtypes and Who Grades: A Multiparametric Approach with Internal Cortical Reference.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeDifferentiating benign from malignant small renal tumors (SRMs) can help to guide clinical decision-making. T1 mapping enables quantitative assessment of T1 relaxation time and may help to evaluate SRMs properties. This study aimed to investigate the possible utility of T1 mapping for identification of SRMs.
methodsThe data set used in this retrospective study, consisted of 104 patients with SRMs (≤ 4 cm). 78 malignant and 25 benign ones respectively. Calculated and compared the quantitative variables (including T1 mapping) between different renal tumors. The clinical features qualitative characteristics were subsequently documented. Finally, the logistic regression models were used to identify independent influencing factors. The diagnostic accuracy of independent influencing factors was represented with the area under the receiver operating characteristic curve (AUC).
resultsThe pre-contrast T1 mapping (T1) and the ratio of T1 reduction in malignance were higher than those in benign SRMs, while post-contrast T1 mapping was lower (all P < 0.025). In multivariable logistic regression, the tumor necrosis (odds ratio (OR) = 20.636, P = 0.005) and T1 (OR = 2.982, P = 0.002) were independent predictors. For the identification of SRMs, the performance of the model achieving an AUC of 0.793 (95% CI 0.701-0.866) when combining two factors.
conclusionQuantitative T1 mapping parameters may be a new potential biomarker for noninvasively distinguishing SRMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.